Inflammatory Cytokines Associate With Neuroimaging After Acute Mild Traumatic Brain Injury
- PMID: 32508732
- PMCID: PMC7248260
- DOI: 10.3389/fneur.2020.00348
Inflammatory Cytokines Associate With Neuroimaging After Acute Mild Traumatic Brain Injury
Abstract
Introduction: Elevated levels of blood-based proinflammatory cytokines are linked to acute moderate to severe traumatic brain injuries (TBIs), yet less is known in acute mild (m)TBI cohorts. The current study examined whether blood-based cytokines can differentiate patients with mTBI, with and without neuroimaging findings (CT and MRI). Material and Methods: Within 24 h of a mTBI, determined by a Glasgow Coma Scale (GCS) between 13 and 15, participants (n = 250) underwent a computed tomography (CT) and magnetic resonance imaging (MRI) scan and provided a blood sample. Participants were classified into three groups according to imaging findings; (1) CT+, (2) MRI+ (CT-), (3) Controls (CT- MRI-). Plasma levels of circulating cytokines (IL-6, IL-10, TNFα), and vascular endothelial growth factor (VEGF) were measured using an ultra-sensitive immunoassay. Results: Concentrations of inflammatory cytokines (IL-6, TNFα) and VEGF were elevated in CT+, as well as MRI+ groups (p < 0.001), compared to controls, even after controlling for age, sex and cardiovascular disease (CVD)-related risk factors; hypertension, and hyperlipidemia. Post-concussive symptoms were associated with imaging groupings, but not inflammatory cytokines in this cohort. Levels of VEGF, IL-6, and TNFα differentiated patients with CT+ findings from controls, with the combined biomarker model (VEGF, IL-6, TNFα, and IL-10) showing good discriminatory power (AUC 0.92, 95% CI 0.87-0.97). IL-6 was a fair predictor of MRI+ findings compared to controls (AUC 0.70, 95% CI 0.60-0.78). Finally, the combined biomarker model discriminated patients with MRI+ from CT+ with an AUC of 0.71 (95% CI 0.62-0.80). Conclusions: When combined, IL-6, TNFα, and VEGF may provide a promising biomarker cytokine panel to differentiate mTBI patients with CT+ imaging vs. controls. Singularly, IL-6 was a fair discriminator between each of the imaging groups. Future research directions may help elucidate mechanisms related to injury severity and potentially, recovery following an mTBI.
Keywords: cardiovascular disease risk; cytokines; inflammation; mild traumatic brain injury; neuroimaging.
Copyright © 2020 Edwards, Pattinson, Guedes, Peyer, Moore, Davis, Devoto, Turtzo, Latour and Gill.
Figures


Similar articles
-
Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI.J Neuroinflammation. 2024 Apr 27;21(1):109. doi: 10.1186/s12974-024-03094-8. J Neuroinflammation. 2024. PMID: 38678300 Free PMC article.
-
Detection of neurofilament-H in serum as a diagnostic tool to predict injury severity in patients who have suffered mild traumatic brain injury.J Neurosurg. 2014 Nov;121(5):1232-8. doi: 10.3171/2014.7.JNS132474. Epub 2014 Sep 5. J Neurosurg. 2014. PMID: 25192482
-
Mild-to-severe traumatic brain injury in children: altered cytokines reflect severity.J Neuroinflammation. 2022 Feb 7;19(1):36. doi: 10.1186/s12974-022-02390-5. J Neuroinflammation. 2022. PMID: 35130911 Free PMC article.
-
Emerging MRI and metabolic neuroimaging techniques in mild traumatic brain injury.Neurol India. 2014 Sep-Oct;62(5):487-91. doi: 10.4103/0028-3886.144434. Neurol India. 2014. PMID: 25387616 Review.
-
Moderate Traumatic Brain Injury: The Grey Zone of Neurotrauma.Neurocrit Care. 2016 Oct;25(2):306-19. doi: 10.1007/s12028-016-0253-y. Neurocrit Care. 2016. PMID: 26927279 Review.
Cited by
-
Proteomic Profiling of Plasma Biomarkers Associated With Return to Sport Following Concussion: Findings From the NCAA and Department of Defense CARE Consortium.Front Neurol. 2022 Jul 19;13:901238. doi: 10.3389/fneur.2022.901238. eCollection 2022. Front Neurol. 2022. PMID: 35928129 Free PMC article.
-
A plasma lipid signature in acute human traumatic brain injury: Link with neuronal injury and inflammation markers.J Cereb Blood Flow Metab. 2025 Mar;45(3):443-458. doi: 10.1177/0271678X241276951. Epub 2024 Aug 26. J Cereb Blood Flow Metab. 2025. PMID: 39188133 Free PMC article.
-
Treatment with the vascular endothelial growth factor-A antibody, bevacizumab, has sex-specific effects in a rat model of mild traumatic brain injury.J Cereb Blood Flow Metab. 2024 Apr;44(4):542-555. doi: 10.1177/0271678X231212377. Epub 2023 Nov 7. J Cereb Blood Flow Metab. 2024. PMID: 37933736 Free PMC article.
-
Association of Traumatic Meningeal Enhancement on MRI With Clinical Recovery in Patients With Traumatic Brain Injury.Neurology. 2025 Mar 25;104(6):e213448. doi: 10.1212/WNL.0000000000213448. Epub 2025 Feb 25. Neurology. 2025. PMID: 39999394
-
Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI.J Neuroinflammation. 2024 Apr 27;21(1):109. doi: 10.1186/s12974-024-03094-8. J Neuroinflammation. 2024. PMID: 38678300 Free PMC article.
References
-
- Cassidy JD, Carroll LJ, Peloso PM, Borg J, von Holst H, Holm L, et al. . Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med. (2004) (43 Suppl):28–60. 10.1080/16501960410023732 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources